HGEN - Humanigen, Inc. Stock Price and Quote

HGEN [NASD]

Index	-	P/E	-	EPS (ttm)	-1.52	Insider Own	11.96%	Shs Outstand	119.08M	Perf Week	-0.67%
Market Cap	15.75M	Forward P/E	-	EPS next Y	-0.34	Insider Trans	0.00%	Shs Float	104.84M	Perf Month	1.13%
Income	-108.70M	PEG	-	EPS next Q	-0.06	Inst Own	6.10%	Short Float / Ratio	6.24% / 1.98	Perf Quarter	40.76%
Sales	3.30M	P/S	4.77	EPS this Y	-66.90%	Inst Trans	-67.36%	Short Interest	6.54M	Perf Half Y	-23.73%
Book/sh	-0.52	P/B	-	EPS next Y	66.00%	ROA	-199.60%	Target Price	-	Perf Year	-95.79%
Cash/sh	0.21	P/C	0.64	EPS next 5Y	12.50%	ROE	287.40%	52W Range	0.09 - 3.39	Perf YTD	11.67%
Dividend	-	P/FCF	-	EPS past 5Y	21.90%	ROI	-	52W High	-96.05%	Beta	-0.83
Dividend %	-	Quick Ratio	0.30	Sales past 5Y	-	Gross Margin	-	52W Low	45.02%	ATR	0.01
Employees	11	Current Ratio	0.30	Sales Q/Q	-80.00%	Oper. Margin	-	RSI (14)	40.70	Volatility	5.56% 9.05%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	79.20%	Profit Margin	-	Rel Volume	0.13	Prev Close	0.14
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	3.31M	Price	0.13
Recom	3.30	SMA20	-8.20%	SMA50	-16.33%	SMA200	-67.13%	Volume	510,428	Change	-0.96%

Jul-13-22

Downgrade

ROTH Capital

Buy → Neutral

$13 → $2

Jul-13-22

Downgrade

H.C. Wainwright

Buy → Neutral

Jul-13-22

Downgrade

Cantor Fitzgerald

Overweight → Neutral

$30 → $2

Sep-10-21

Downgrade

Jefferies

Buy → Hold

Sep-09-21

Reiterated

H.C. Wainwright

Buy

$36 → $28

Sep-09-21

Downgrade

JP Morgan

Neutral → Underweight

Sep-09-21

Downgrade

Credit Suisse

Outperform → Neutral

Jun-11-21

Initiated

Credit Suisse

Outperform

$28

May-07-21

Initiated

Oppenheimer

Outperform

$30

Feb-23-21

Initiated

JP Morgan

Neutral

$21

Show Previous Ratings

Nov-14-22 04:01PM	Humanigen Reports Third Quarter 2022 Financial Results Newsfile +7.87%
Nov-10-22 08:02AM	Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference Newsfile +6.30%
Oct-31-22 08:01AM	Humanigen Announces Retention of SC&H Capital as Financial Advisor Newsfile
Sep-12-22 06:55AM	Humanigen and SAHMRI Announce Expansion of the PREACH-M Study of Lenzilumab in CMML Newsfile +10.00%
Sep-07-22 06:55AM	Humanigen to Participate in H.C. Wainwright and Cantor Investor Conferences in September 2022 Newsfile
04:00PM	Loading…
Aug-12-22 04:00PM	Humanigen Reports Second Quarter 2022 Financial Results Business Wire
Jul-26-22 07:30AM	Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones Newsfile
Jul-13-22 05:22PM	Martin Shkreli's onetime company loses 80% of value as Covid drug trial fails American City Business Journals -79.56%
12:41PM	Humanigen Stock: Why It Crashed and Where Its Headed TipRanks
11:04AM	Pandemic is still a public health emergency, warns WHO, urging greater surveillance including testing and sequencing MarketWatch
08:09AM	Humanigen's stock tumbles 67% after sharing new clinical data for its COVID-19 treatment MarketWatch
Jul-12-22 08:30PM	Humanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B Business Wire
Jul-06-22 11:34PM	Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein Business Wire +14.36%
Jun-30-22 08:19AM	NIH/NIAID Locks ACTIV-5/BET-B Database Business Wire
Jun-16-22 06:30AM	Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom Business Wire -5.73%
07:04AM	Loading…
Jun-15-22 07:04AM	Insiders who purchased this year lose US$14k as Humanigen, Inc. (NASDAQ:HGEN) stock drops to US$2.18 Simply Wall St.
Jun-03-22 07:00AM	Humanigen Announces Participation and Presentation at Multiple Conferences in June Business Wire +11.87%
May-24-22 06:30AM	Humanigen Announces Participation and Presentation at H.C. Wainwright Global Investment Conference Business Wire
May-11-22 08:43PM	Humanigen: A Transformative Year Awaits, Says Analyst TipRanks -11.33%
May-09-22 06:15AM	Investors in Humanigen (NASDAQ:HGEN) from a year ago are still down 89%, even after 14% gain this past week Simply Wall St. -12.56%
May-05-22 04:00PM	Humanigen Reports First Quarter 2022 Financial Results Business Wire -7.54%
May-04-22 07:00AM	Humanigen Announces Participation and Presentation at Multiple Conferences in May Business Wire
Apr-19-22 06:30AM	Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS Business Wire
Apr-07-22 01:35PM	Humanigen, Inc.'s (NASDAQ:HGEN) Path To Profitability Simply Wall St. -5.84%
Mar-17-22 03:47PM	Insiders Buy These 2 Stocks at Discounted Prices Analysts Say They Have Over 200% Upside Potential TipRanks +7.20%
Feb-28-22 01:05PM	Humanigen Reports Year-End 2021 Financial Results Business Wire
Feb-25-22 05:55AM	Humanigen to Present and Participate at Multiple Investor Events in March Business Wire
Feb-11-22 05:55AM	Humanigen to Present at BIO CEO & Investor Conference Business Wire
Feb-09-22 11:55PM	Humanigen Launches Managed Access Program for Lenzilumab Business Wire
Feb-08-22 11:55PM	Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France Business Wire -6.07%
08:26AM	Loading…
Feb-06-22 08:26AM	What Kind Of Shareholders Own Humanigen, Inc. (NASDAQ:HGEN)? Simply Wall St.
Jan-18-22 05:55AM	Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab Business Wire -5.61%
Jan-10-22 05:55AM	Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T Business Wire
Jan-06-22 03:11PM	Why 2022 Holds Hope for Humanigen Stock, According to This Analyst TipRanks -5.61%
Jan-05-22 06:05AM	Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved Business Wire -11.53%
Jan-04-22 05:55AM	Humanigen to Present at Investor Conferences January 7 and 13, 2022 Business Wire
Jan-03-22 05:55AM	Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels Business Wire
Dec-15-21 08:59AM	Humanigen Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference in January 2022 Business Wire
Dec-01-21 06:45PM	Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update Business Wire -8.09%
06:30PM	The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results Business Wire
Nov-22-21 06:30AM	Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021 Business Wire
Nov-16-21 07:47AM	Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference Business Wire
Nov-12-21 04:00PM	Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update Business Wire
Nov-11-21 06:30AM	Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease Business Wire
Nov-07-21 08:34AM	Investors in Humanigen (NASDAQ:HGEN) have made a impressive return of 172% over the past three years Simply Wall St.
Nov-05-21 10:34AM	Humanigen Announces Release of Abstracts at ASH Business Wire -8.90%
07:04AM	Humanigen: All You Need to Know Right Now TipRanks
Nov-02-21 08:30AM	Humanigen Announces Participation and Presentation at Multiple Conferences in November Business Wire +5.54%
Oct-26-21 05:31PM	European Commission Selects Humanigens Lenzilumab as One of the 10 Most Promising Treatments for COVID-19 Business Wire +5.61%
06:30AM	First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML) Business Wire
Oct-22-21 07:00AM	Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM21 Business Wire
Oct-20-21 07:00AM	Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors Business Wire
Oct-19-21 07:00AM	Humanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting Highlighting C-Reactive Protein as a Biomarker for Identifying Patients Most Likely to Benefit from treatment with Lenzilumab Business Wire
Oct-11-21 12:53PM	Humanigens Budget Impact Model Demonstrates Lenzilumabs Potential Positive Economic Value in Hospitalized COVID-19 Patients Business Wire
12:23PM	Humanigen Stock to $28? This Analyst Thinks So TipRanks
Oct-08-21 02:00AM	Humanigen Signs Contract With Clinigen for Lenzilumab Managed Access Program in Europe Business Wire
Oct-04-21 11:00PM	Humanigen Announces Participation and Presentation at Multiple Conferences in October Business Wire
Oct-01-21 09:00AM	Humanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UKs MHRA Business Wire
Sep-29-21 08:00AM	Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021 Business Wire
Sep-28-21 08:28AM	Humanigen Announces the European Medicines Agency Has Appointed a Rapporteur and Co-rapporteur as Part of the Process Related to the Planned Submission of a Marketing Authorization Application (MAA) for Lenzilumab Business Wire
Sep-27-21 10:58AM	Humanigen: Lenzilumab Could Reach the UK Market in 1Q22, Says Analyst TipRanks
Sep-21-21 05:02PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN Newsfile
Sep-20-21 12:38AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN PR Newswire -8.20%
Sep-14-21 12:56PM	Humanigen Announces Participation and Presentation at Multiple Conferences in September Business Wire
Sep-10-21 01:10PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Humanigen, Inc. (HGEN) Investigation ACCESSWIRE -13.68%
11:52AM	Has Humanigen Stock Hit Bottom? Oppenheimer Looks for the Silver Lining TipRanks
Sep-09-21 09:43PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN PR Newswire -47.25%
02:15PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Humanigen, Inc. (HGEN) Investigation ACCESSWIRE
12:16AM	FDA has declined Humanigens Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients Business Wire
Aug-25-21 09:14AM	Humanigen: Lenz Could Become a $1.45 Billion Drug, if Approved, Says Analyst TipRanks
Aug-12-21 04:00PM	Humanigen Reports Second Quarter 2021 Financial Results Business Wire
Aug-09-21 03:19AM	Is Humanigen (NASDAQ:HGEN) Using Too Much Debt? Simply Wall St. +7.55%
Aug-04-21 06:00AM	Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients Business Wire
Aug-02-21 02:02PM	Humanigen: Shares Could More Than Double From Here, Says 5-Star Analyst TipRanks
Jul-30-21 11:06AM	NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19 Business Wire
Jul-26-21 08:00AM	Ensysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development GlobeNewswire
Jul-22-21 09:59AM	Humanigens Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab Business Wire
Jul-13-21 06:51PM	Humanigen: Covid-19 Drug Has Good Odds for EUA Approval, Says Analyst TipRanks
Jul-12-21 08:40AM	Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock? Zacks
Jul-09-21 06:30AM	UKs MHRA accepts Humanigens submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review Business Wire
Jun-28-21 11:46AM	Humanigen Inc. Added to Russell 3000(R) Index Newsfile
Jun-25-21 02:27AM	What Is The Ownership Structure Like For Humanigen, Inc. (NASDAQ:HGEN)? Simply Wall St.
Jun-14-21 06:30AM	Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdoms Medicines and Healthcare Products Regulatory Agency (MHRA) Business Wire
Jun-07-21 08:00AM	Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations Business Wire +11.30%
Jun-03-21 08:00AM	Humanigen to Present at the 2021 LD Micro Invitational XI Business Wire -5.79%
May-28-21 09:00AM	Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19 Business Wire -11.04%
May-26-21 08:30AM	GM-CSF Gene-Edited CAR-T Data to be Presented at International Society for Cell & Gene Therapy Annual Meeting 2021 Business Wire +8.35%
May-19-21 07:00AM	Humanigen to Present at Jefferies Healthcare Conference Business Wire
May-17-21 08:00AM	Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab Business Wire +6.03%
May-13-21 04:01PM	Humanigen Reports First Quarter 2021 Financial Results Business Wire
10:15AM	Are Options Traders Betting on a Big Move in Humanigen (HGEN) Stock? Zacks
May-11-21 04:19AM	Calculating The Intrinsic Value Of Humanigen, Inc. (NASDAQ:HGEN) Simply Wall St.
May-05-21 11:53AM	Humanigen Announces Publication of Results From Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab in Hospitalized COVID-19 Patients Business Wire +5.43%
Apr-21-21 07:00AM	Humanigen Appoints Dr. Adrian Kilcoyne to the role of Chief Medical Officer Business Wire +10.71%
Apr-19-21 07:00AM	Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study Business Wire -5.70%
Apr-09-21 08:19AM	Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme Business Wire
08:02AM	Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock? Zacks
Apr-06-21 02:02PM	Humanigen Announces Closing of Public Offering of Common Stock Business Wire
Mar-30-21 08:08PM	Humanigen Announces Pricing of Public Offering of Five Million Shares of Common Stock Business Wire
Mar-29-21 04:11PM	Humanigen Announces Proposed Public Offering of Five Million Shares of Common Stock Business Wire +54.47%

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chappell Dale	Chief Scientific Officer	May 20	Buy	2.23	545,488	1,215,347	8,675,081	May 20 05:57 PM
Chappell Dale	Chief Scientific Officer	May 19	Buy	2.19	323,808	707,844	8,293,240	May 20 05:57 PM
Chappell Dale	Chief Scientific Officer	May 18	Buy	1.96	173,700	340,799	8,066,575	May 20 05:57 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience